Mainz Biomed N.V. is set to share groundbreaking findings from its eAArly DETECT study at the upcoming Digestive Disease Week (DDW) 2024 in Washington D.C. The study focuses on the early detection of colorectal cancer, a critical aspect of cancer research and prevention.
The eAArly DETECT study, conducted at 21 specialized gastroenterology sites in the US and involving 254 clinical patients, has yielded impressive results. The study revealed a sensitivity of 97% for colorectal cancer, along with a specificity of 97%. Additionally, the test showed a sensitivity of 82% for advanced adenomas, a significant precursor to colorectal cancer.
Mainz Biomed’s innovative multimodal screening test combines various biomarkers, including the Fecal Immunochemical Test (FIT), DNA, and mRNA, with a unique artificial intelligence (AI) and machine learning algorithm. This combination enables the differentiation between colorectal cancer, advanced adenomas, non-advanced adenomas, and samples with no significant findings.
By accurately analyzing this array of biomarkers, Mainz Biomed aims to enhance early detection rates for colorectal cancer and its precursors, ultimately shifting the focus from detection to prevention. This shift reflects the company’s dedication to reducing cancer mortality rates globally, a crucial goal in the field of cancer research.
The presentation at DDW will focus on the test’s ability to detect colorectal cancer and precancerous lesions through a non-invasive stool-based approach. Titled NOVEL STOOL-BASED NON-INVASIVE EARLY DETECTION OF COLORECTAL CANCER AND PRECANCEROUS LESIONS BY CLASSIC FIT COMBINED WITH NUCLEIC ACID-BASED BIOMARKER SIGNATURES, the session is sponsored by AGA and will explore the significant advancements made in cancer detection and prevention through Mainz Biomed’s innovative approach.
Stay tuned for more updates from Digestive Disease Week 2024 as Mainz Biomed presents its cutting-edge research in the fight against colorectal cancer.
